First Acquisition of Theraclion’s Echopulse® in Switzerland

Regulatory News:

Theraclion (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that the Ente Ospedaliero Cantonale (EOC), the first center to offer echotherapy in Switzerland for the treatment of benign thyroid nodules, has exercised its option to buy an Echopulse® system. Following a one-year rental period, the EOC purchased the system.

"Echopulse® is a very promising non-invasive approach to treating benign thyroid nodules,” said Prof. Lucas Giovanella, Director of the EOC Competence Centre for Thyroid Diagnosis and Treatment and Head of the Nuclear Medicine Department and the PET-CT Center. "We are highly interested by Theraclion’s technology as it completes our panel of treatment options for benign thyroid diseases. Theraclion’s specialists provided dedicated support to our clinician team in the initial phase and we are very happy now to continue to work with Theraclion.”

The EOC is a group of all public hospitals operating in Ticino, a region located in the Italian-speaking region of Switzerland. The group is comprised of six general hospitals and two specialized clinics. A unique feature of this group’s structure is the presence of centers of excellence that serve patients from the region regardless of the hospital at which they initially present. The EOC is responsible for the majority of all health care delivered in Ticino.

"Continuing our collaboration with this Center of Excellence for the management of thyroid pathologies represents strong validation and trust of our technology by renowned specialists such as Prof. Giovanella,” said David Caumartin, CEO of Theraclion. "EOC’s purchase of an Echopulse® system demonstrates the growing support of echotherapy among alternative therapeutic and surgical options for effective and safe treatment of patients.”

About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 35 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Theraclion is listed on Alternext Paris
PEA-PME eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

View source version on businesswire.com: http://www.businesswire.com/news/home/20161207005883/en/